Gledepa Met 5/1000 mg

Gledepa Met 5/1000 mg contains Dapagliflozin 5 mg + Metformin 1000 mg (as Metformin Hydrochloride). Prescription required.

Treatment of type 2 diabetes mellitus in adults to improve glycaemic control (as an adjunct to diet and exercise), especially when control is inadequate with metformin or when combination therapy is appropriate.

Dapagliflozin is an SGLT2 inhibitor that reduces glucose reabsorption in the kidneys, increasing urinary glucose excretion and lowering blood sugar. Metformin decreases hepatic glucose production and improves insulin sensitivity, reducing glucose absorption and improving peripheral glucose uptake.

Oral tablet. Take exactly as prescribed, usually once or twice daily with meals to reduce stomach upset (metformin component). Swallow whole with water; do not crush/chew. Maintain adequate hydration; follow diet/exercise advice and monitor blood glucose as directed.

Nausea, vomiting, diarrhoea, abdominal discomfort, loss of appetite, genital fungal infections, urinary tract infection, increased urination, thirst, dizziness, headache

Type 2 diabetes only (not for type 1 diabetes). Risk of lactic acidosis with metformin (higher risk in kidney impairment, dehydration, severe infection, hypoxia, excessive alcohol); stop and seek urgent care if rapid breathing, severe weakness, abdominal pain, or drowsiness occur. Dapagliflozin can cause genital mycotic infections, UTIs, volume depletion/low BP, and rarely diabetic ketoacidosis (may occur even with near-normal glucose); seek care for nausea/vomiting, abdominal pain, breathlessness. Assess kidney function before and during treatment; avoid/use with caution in renal impairment as per clinician. Temporarily withhold during major surgery, acute illness, prolonged fasting, or before iodinated contrast procedures per doctor advice. Monitor for hypoglycaemia if used with insulin/sulfonylureas.

Insulin and sulfonylureas (increased hypoglycaemia risk), diuretics (increased dehydration/low BP risk), ACE inhibitors/ARBs and other antihypertensives (additive BP lowering), iodinated contrast media (increased lactic acidosis risk—hold metformin around procedure as advised), carbonic anhydrase inhibitors e.g. topiramate/acetazolamide (increased metabolic acidosis risk), alcohol (increases lactic acidosis risk), cationic drugs affecting renal tubular secretion e.g. cimetidine (may increase metformin levels)

Store below 25°C, in a dry place, protected from light and moisture. Keep out of reach of children.

Xigduo XR 5/1000 Tablet, Dapamet 5/1000 Tablet, Dapanorm M 5/1000 Tablet, Dapamix M 5/1000 Tablet, Forxiga Met 5/1000 Tablet